{
    "eid": "2-s2.0-85081934762",
    "title": "Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Social Psychology",
            "@code": "3207",
            "@abbrev": "PSYC"
        },
        {
            "@_fa": "true",
            "$": "Health (social science)",
            "@code": "3306",
            "@abbrev": "SOCI"
        },
        {
            "@_fa": "true",
            "$": "Clinical Psychology",
            "@code": "3203",
            "@abbrev": "PSYC"
        },
        {
            "@_fa": "true",
            "$": "Gerontology",
            "@code": "2909",
            "@abbrev": "NURS"
        },
        {
            "@_fa": "true",
            "$": "Geriatrics and Gerontology",
            "@code": "2717",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Alzheimer\u2019s disease",
        "cannabinoids",
        "cannabis",
        "dementia"
    ],
    "authors": [
        "Thammanard Charernboon",
        "Tiraya Lerthattasilp",
        "Thitipon Supasitthumrong"
    ],
    "citedby-count": 19,
    "ref-count": 29,
    "ref-list": [
        "Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia",
        "Cannabinoids for treatment of Alzheimer\u2019s disease: Moving toward the clinic",
        "CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice",
        "Prescription of a THC/CBD-based medication to patients with dementia: A pilot study in Geneva",
        "Prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: A cross-sectional descriptive study in Thailand",
        "Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation",
        "GRADE: An emerging consensus on rating quality of evidence and strength of recommendations",
        "Randomized placebo-controlled trial of Nabilone for agitation in Alzheimer\u2019s disease",
        "International union of pharmacology. XXVII. Classification of cannabinoid receptors",
        "Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the guideline development subcommittee of the American academy of neurology",
        "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration",
        "A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders",
        "Actigraphy in agitated patients with dementia. Monitoring treatment outcomes",
        "Systematic review and meta-analysis of cannabinoids in palliative medicine",
        "The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation",
        "Cannabinoid pharmacology: The first 66 years",
        "Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer\u2019s disease: Study protocol for a cross-over randomized controlled trial",
        "Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot Study",
        "Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial",
        "Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial",
        "Tetrahydrocannabinol in behavioral disturbances in dementia: A crossover randomized controlled trial",
        "Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease",
        "Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia",
        "Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia",
        "In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer\u2019s disease",
        "Dextrometorphan-paroxetine, but not dronabinol, effective for treatment-resistant aggression and agitation in an elderly patient with Lewy Body dementia",
        "Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms",
        "Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: A network meta-analysis",
        "The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: Systematic review and meta-analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60012521",
            "affilname": "Thammasat University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012521",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}